Technical Analysis for ONCR - Oncorus, Inc.

Grade Last Price % Change Price Change
grade D 15.5 1.44% 0.22
ONCR closed up 1.44 percent on Friday, October 23, 2020, on 12 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical ONCR trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Calm After Storm Range Contraction 1.44%
New 52 Week Closing Low Bearish 3.33%
Hot IPO Pullback Bullish Swing Setup 3.33%
Calm After Storm Range Contraction 3.33%
Hot IPO Pullback Bullish Swing Setup -0.26%
Hot IPO Pullback Bullish Swing Setup -2.94%
NR7 Range Contraction -2.94%
Inside Day Range Contraction -2.94%
Hot IPO Pullback Bullish Swing Setup -2.15%
Older End-of-Day Gignals for ONCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 3 days ago
Down 1% 3 days ago
Up 3% 3 days ago
Up 2% 3 days ago
Up 1% 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Oncolytics Biotech Brain Cancer Oncolytic Virus

Is ONCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.3
52 Week Low 14.6
Average Volume 112,275
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 15.95
Average True Range 1.45
ADX 0.0
+DI 26.15
-DI 13.00
Chandelier Exit (Long, 3 ATRs ) 14.96
Chandelier Exit (Short, 3 ATRs ) 18.94
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.16
MACD Signal Line -0.07
MACD Histogram -0.084
Fundamentals Value
Market Cap 338.61 Million
Num Shares 21.8 Million
EPS
Price-to-Sales 0.00
Price-to-Book 12.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.70
Resistance 3 (R3) 16.70 16.30 16.50
Resistance 2 (R2) 16.30 15.99 16.30 16.43
Resistance 1 (R1) 15.90 15.81 16.10 15.90 16.37
Pivot Point 15.50 15.50 15.60 15.50 15.50
Support 1 (S1) 15.10 15.19 15.30 15.10 14.63
Support 2 (S2) 14.70 15.01 14.70 14.57
Support 3 (S3) 14.30 14.70 14.50
Support 4 (S4) 14.30